Kiura, K., Imamura, F., Kagamu, H., Matsumoto, S., Hida, T., Nakagawa, K., . . . Nishio, M. (2018). Phase 3 study of ceritinib vs chemotherapy in ALK-rearranged NSCLC patients previously treated with chemotherapy and crizotinib (ASCEND-5): Japanese subset. Jpn J Clin Oncol.
Style de citation ChicagoKiura, Katsuyuki, et al. "Phase 3 Study of Ceritinib Vs Chemotherapy in ALK-rearranged NSCLC Patients Previously Treated With Chemotherapy and Crizotinib (ASCEND-5): Japanese Subset." Jpn J Clin Oncol 2018.
Style de citation MLAKiura, Katsuyuki, et al. "Phase 3 Study of Ceritinib Vs Chemotherapy in ALK-rearranged NSCLC Patients Previously Treated With Chemotherapy and Crizotinib (ASCEND-5): Japanese Subset." Jpn J Clin Oncol 2018.
Attention : ces citations peuvent ne pas être correctes à 100%.